Design, Synthesis and Characterization of Cyclic NU172 Analogues: A Biophysical and Biological Insight

NU172—a 26-mer oligonucleotide able to bind exosite I of human thrombin and inhibit its activity—was the first aptamer to reach Phase II clinical studies as an anticoagulant in heart disease treatments. With the aim of favoring its functional duplex-quadruplex conformation and thus improving its enz...

Descripción completa

Detalles Bibliográficos
Autores principales: Riccardi, Claudia, Meyer, Albert, Vasseur, Jean-Jacques, Cavasso, Domenico, Russo Krauss, Irene, Paduano, Luigi, Morvan, François, Montesarchio, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312020/
https://www.ncbi.nlm.nih.gov/pubmed/32485818
http://dx.doi.org/10.3390/ijms21113860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312020/
https://www.ncbi.nlm.nih.gov/pubmed/32485818
http://dx.doi.org/10.3390/ijms21113860

Ejemplares similares